Home › Trials › NCT03151629

International registry for men with advanced prostate cancer

International Registry for Men With Advanced Prostate Cancer (IRONMAN)

Observational Prostate Cancer Clinical Trials Consortium · NCT03151629

This study is creating a global registry of at least 5,000 men with advanced prostate cancer to see how their care and treatment differ around the world.

Quick facts

Study typeObservational
Enrollment5000 (estimated)
Ages21 Years and up
SexMale
SponsorProstate Cancer Clinical Trials Consortium Academic / other
Locations121 sites (Birmingham, Alabama and 120 other locations)
Trial IDNCT03151629 on ClinicalTrials.gov

What this trial studies

The IRONMAN initiative aims to create a prospective international registry of at least 5,000 men diagnosed with advanced prostate cancer, including those with metastatic hormone-sensitive prostate cancer (mHSPC) and castration-resistant prostate cancer (CRPC). This observational study will recruit participants from various academic and community practices across multiple countries, including the US, UK, and several others. Detailed data will be collected at enrollment and during follow-up to understand the variations in care and treatment for advanced prostate cancer globally.

Who should consider this trial

Good fit: Ideal candidates include males aged 21 and older with confirmed prostate adenocarcinoma and specific disease characteristics.

Not a fit: Patients with a previous diagnosis of a second malignancy requiring systemic therapy may not benefit from this study.

Why it matters

Potential benefit: If successful, this registry could lead to improved understanding and treatment outcomes for men with advanced prostate cancer.

How similar studies have performed: Other studies have shown success with similar registry approaches, indicating potential for valuable insights in prostate cancer treatment.

Eligibility criteria

Show full inclusion / exclusion criteria 
• Willing and able to provide written informed consent and privacy authorization for the release of personal health information.

NOTE: Privacy authorization may be either included in the informed consent or obtained separately.

* Males 21 years of age and above
* Histological or cytological confirmed prostate adenocarcinoma from TRUS biopsy, radical prostatectomy or TURP Or Documented histopathology or cytopathology of prostate adenocarcinoma from a biopsy of a metastatic site Or Metastatic disease typical of prostate cancer (i.e., involving bone or pelvic lymph nodes or para-aortic lymph nodes) AND a serum concentration of PSA \>20ng/mL at the time of initial prostate cancer diagnosis
* No previous diagnosis of a second, non-prostate malignancy that requires additional systemic therapy except cancer in situ of bladder and basal cell cancer of skin

Where this trial is running

Birmingham, Alabama and 120 other locations

+71 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Prostate Cancer
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.